Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial.
Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK; Radiation Therapy Oncology Group 90-03 Trial. Calvin DP, et al. Among authors: byhardt rw. Am J Clin Oncol. 2007 Aug;30(4):406-19. doi: 10.1097/COC.0b013e3180342fd4. Am J Clin Oncol. 2007. PMID: 17762442
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. Khor LY, et al. Among authors: byhardt rw. J Clin Oncol. 2009 Jul 1;27(19):3177-84. doi: 10.1200/JCO.2008.19.8267. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470936 Free PMC article. Clinical Trial.
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. Cox JD, et al. Among authors: byhardt rw. J Clin Oncol. 1990 Sep;8(9):1543-55. doi: 10.1200/JCO.1990.8.9.1543. J Clin Oncol. 1990. PMID: 2167952 Clinical Trial.
Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.
Cox JD, Pajak TF, Marcial VA, Hanks GE, Mohiuddin M, Fu KK, Byhardt RW, Rubin P. Cox JD, et al. Among authors: byhardt rw. Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):515-21. doi: 10.1016/0360-3016(90)90054-n. Int J Radiat Oncol Biol Phys. 1990. PMID: 2180866 Clinical Trial.
Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.
Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M 3rd. Cox JD, et al. Among authors: byhardt rw. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):493-8. doi: 10.1016/0360-3016(93)90371-2. Int J Radiat Oncol Biol Phys. 1993. PMID: 8226140 Clinical Trial.
138 results